Navigation Links
Max Neeman International to Open Phase I/IIa Unit
Date:9/23/2009

RESEARCH TRIANGLE PARK, N.C., Sept. 23 /PRNewswire/ -- Max Neeman International, a leading Indian CRO, announced a partnership with Max Healthcare to open a Phase I/IIa clinical trial unit at Max Super Speciality Hospital, New Delhi, India. This proof of concept unit will allow Pharmaceutical, Biotech & Device companies the option to complete a critical part of the development process across multiple therapeutic areas quickly and with the highest quality.

The new Phase I/IIa unit will evaluate compounds/devices developed both in India and in other countries. This unit will provide end-to-end services and will have approximately 24 beds, with plans to expand this number to 50 to meet predicted growth in demand.

This new Phase I/IIa unit will draw on the experience of its partners and the expertise of local clinicians and scientists to deliver studies in accordance with global standards and within the regulatory framework in India.

Our partner Max Healthcare, with over 800 beds and 8 hospitals in Delhi is one of the leading hospital chains in India and has an outstanding reputation and track record for quality health care provision in India.

About Max Healthcare

With over 800 beds and 8 hospitals in Delhi, and with over 1500 physicians and 3000 support staff - Max Healthcare is one of a leading chain of hospitals in India. Its state of the art infrastructure, over 225 ICU beds and most advanced technologies makes it one of the best hospitals in India. http://www.maxhealthcare.in

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India providing a full range of clinical services to global Pharmaceutical, Biotech and Device companies. Operational since 2001, it is an ISO 9001:2000 certified CRO for Monitoring, Site Management and Data Management Services. Presently, it is active in 22 cities with 5 regional offices. Please contact Donald Swankie, Vice President of Business Development for more information (donald.swankie@neeman-medical.com/ +1.919.424.3345). http://www.neeman-medical.com


'/>"/>
SOURCE Max Neeman International
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
3. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
4. Arrow International Files and Mails Definitive Proxy Materials
5. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
6. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
7. Viragen International to Reverse Split Its Common Stock
8. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
9. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
10. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
11. Biosafety and Biosecurity International Conference 2007 to be held in Abu Dhabi from November 12 to 14
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... After her brain ... doctors gave her only a few months to live. Now a paper publishing ... stabilized Rosendahl’s disease and increased both the quantity and quality of her life: ...
(Date:1/12/2017)... 2017 The report "Direct-Fed Microbials Market by Type (Lactic Acid Bacteria ... and Region - Global Forecast to 2022", published by MarketsandMarkets, the global market ... to reach USD 1,399.6 Million by 2022, at a CAGR of 6.96% from ... ... MarketsandMarkets Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... As a graduate student, Scarlet ... pathogens that cause malaria and tuberculosis. Seeing firsthand the ravages those diseases visit ... as an assistant professor of biology and biotechnology at Worcester Polytechnic Institute (WPI), ...
(Date:1/11/2017)... Linda, Ca (PRWEB) , ... January 11, 2017 ... ... resistance in pathogens are observed in clinical settings, it is becoming increasingly clear ... problem. An over-reliance on culture-based methods, the standard in the study of clinical ...
Breaking Biology Technology:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the ... market is expected to grow from USD 4.03 billion ... a CAGR of 29.3% between 2016 and 2022. The ... demand for smart devices, government initiatives, and increasing penetration ... is expected to grow at a high rate during ...
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):